Healing of disease by
suppressing, inducing and enhancing immune response is termed as immunotherapy.
There are two types of immunotherapy namely suppression immunotherapy and
activation immunotherapy. Activation immunotherapy is intended to extract or
strengthen immune response whereas suppression immunotherapy decrease or
restrain the immune response. Cancer immunotherapy is type of activation
immunotherapy. Immune system is a compilation of special cells, substances and
organs that defend from infections and other diseases, and also safeguard from
cancer in different ways. The immune system keeps path of all substances found
in body. Foreign substances that immune system does not identify raise an
alert, causing the immune system to take action against it. The immune response
can demolish everything containing the distant matter, such as microbes or
cancer cells.
Browse Full Report @ http://www.syndicatemarketresearch.com/market-analysis/cancer-immunotherapy-market-global-industry-analysis-size-share.html
Immunotherapy earned
fame with rising facts about the measures of immune system. Immunotherapy has
been increasing in treating several types of cancer rather than other treatment
options like radiation and chemotherapy. Immune system shields from infections
by wandering all over the body to protect it. The foremost drivers for the
increase of immunotherapy medicine market are escalating occurrence of diverse
types of cancer and focus on therapies with less side effects and faster drug
endorsement processes. The market for cancer immunotherapy is probable to
increase with growing population suffering from cancer. Similarly, cancer
immunotherapy has been verified to be successful in treating cancer which will
accelerate the adoption of cancer immunotherapy for cancer treatment.
Conversely, the increasing price of cancer therapies and partial information of
cancer immunobiology are the chief factors affect the escalation of immunotherapy
drugs market. Further, growing R&D for cancer immunotherapy by researchers
will emphasize the growth of cancer immunotherapy market. Scientists have
invented a range of new cancer vaccines and monoclonal antibodies for heighten
the list of cancer immunotherapy products. Cancer vaccines have been set up to
make a privileged income than the common drugs, due to the nature of the
sickness and the necessity for these vaccines.
The report provides a
comprehensive view on the cancer immunotherapy market we have included a
detailed value chain analysis. To understand the competitive landscape in the
market, an analysis of Porter’s Five Forces model for the cancer immunotherapy
market has also been included. The study encompasses a market attractiveness analysis,
wherein product segments are benchmarked based on their market size, growth
rate and general attractiveness. The report also analyzes several driving and
restraining factors and their impact on the market during the forecast period.
Get Free Request Sample @ http://goo.gl/7xavyM
The cancer immunotherapy
market can be segmented on the basis of products, type and region. Adopted Cell
Therapy (ACT), Bispecific Monoclonal Antibodies, PD-1/PD-L1 inhibitors,
Interferons IDO Inhibitors, T-Cell Therapy Cytokines, Chimeric Antigen Receptor
(CAR), Antibody Drug Conjugates (ADCs), Dendritic Cells and Cytokines are some
of the key products of cancer immunotherapy. Depending on type cancer
immunotherapy market is bifurcated into, granulocyte macrophage-colony
stimulating factor (GM-CSF), adoptive cell transfer, cytokines, immune
checkpoint inhibitors, interleukins, monoclonal antibodies, interferon and
immunomodulators. Monoclonal antibodies had major contribution in 2014 and
estimated to be record fastest growth over the predicted period. Diverse
function of monoclonal antibody to bind cancer specific cell to prevent strong
cells from infection, would propel the use of monoclonal antibodies. Monoclonal
antibodies are synthetic versions of proteins for immune system. Cancer
vaccines, also known as cell based therapy, are cancer vaccines that aid to
treat cancer by injecting firm substances (cancer vaccines) into the body to
activate immune response beside cancer. Non-specific immunotherapy improves the
immune system in common way and assist immune system to attack cancer cells.
The report covers
forecast and analysis for the cancer immunotherapy market on a global and
regional level. The study provides significant data of 2014 along with
estimated from 2014 to 2020 based on revenue (USD Million). The report also offers
detailed competitive landscape of the global cancer immunotherapy market. It
includes company market share analysis, product portfolio of the major industry
participants. The report provides detailed segmentation of the cancer
immunotherapy market based on product segment, type segment and region.
Get
Illustrative Sample before buying: http://goo.gl/jEjxVJ
Geographically, cancer
immunotherapy market is segmented into North America, Europe, Asia Pacific,
Latin America and Middle East Africa. North America dominated the market in
2014 with major share due to increased death and morbidity rates of cancer
sufferer. High population of specific gender victims is another important
factor for growth of immunotherapy in this region. Furthermore, escalating
alertness initiative about cancer by government has lead further number of
patients to undergo treatment. Asia Pacific is anticipated to emerge as
prominent regional market due to improved healthcare expenses by developing
countries in this region.
In order to meet
increasing requirement of high populace in Asia Pacific region different
companies are striving to fulfill the rising need of immunotherapy. The cancer
immunotherapy includes major companies such as F. Hoffmann-La Roche Ltd,
Viralytics, Novartis Pharmaceuticals Corporation, GlaxoSmithKline
Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers
Squibb, Merck & Co. and Celgene Corp.
The report segments of
the cancer immunotherapy market into:
Cancer Immunotherapy Market: Product Segment Analysis
- Adopted
Cell Therapy (ACT)
- Bispecific
Monoclonal Antibodies
- PD-1/PD-L1
inhibitors
- Interferons
IDO Inhibitors
- T-Cell
Therapy Cytokines
- Chimeric
Antigen Receptor (CAR)
- Antibody
Drug Conjugates (ADCs)
- Dendritic
Cells
- Cytokines
Cancer Immunotherapy Market: Type Segment Analysis
- Granulocyte
macrophage-colony stimulating factor (GM-CSF)
- Adoptive
cell transfer
- Immune
checkpoint inhibitors
- Interleukins
- Monoclonal
antibodies
- Interferon
- Immunomodulators
Cancer Immunotherapy Market: Regional Segment Analysis
- North
America
- U.S.
- Europe
- UK
- France
- Germany
- Asia
Pacific
- China
- Japan
- India
- Latin
America
- Brazil
- Middle
East & Africa
Contact Us
3422 SW 15 Street, Suit #8138,
Deerfield Beach,Florida 33442,
USATel: +1-386-310-3803GMT Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Deerfield Beach,Florida 33442,
USATel: +1-386-310-3803GMT Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
No comments:
Post a Comment